budesonide + ipratropium bromide + salbutamol

This drug is a combination of three active pharmaceutical ingredients—budesonide, ipratropium bromide, and salbutamol—administered via inhalation, typically as a nebulized solution. Budesonide is an inhaled corticosteroid that reduces airway inflammation by inhibiting multiple types of inflammatory cells and mediators. Ipratropium bromide is an anticholinergic bronchodilator that blocks muscarinic receptors in the airways, leading to relaxation of bronchial smooth muscle and reduced mucus secretion. Salbutamol (also known as albuterol) is a short-acting beta-2 adrenergic receptor agonist that causes rapid bronchodilation by relaxing airway smooth muscle. The combination targets different mechanisms involved in obstructive airway diseases such as asthma and chronic obstructive pulmonary disease (COPD), providing synergistic effects for improved symptom control, reduction of exacerbations, and enhanced lung function[4][5][1]. This triple therapy may be used off-label or compounded in clinical settings for patients with severe or refractory symptoms.